Health-related quality of life in multiple sclerosis: Current evidence, measurement and effects of disease severity and treatment

CNS Drugs

Volumn 22, Issue 10, 2008, Pages 827-839

  Rudick, Richard A ^a   Miller, Deborah M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Glatiramer acetate, therapeutic use; Immunosuppressants, therapeutic use; Interferon alpha 2a, therapeutic use; Interferon beta 1a, therapeutic use; Interferon beta 1b, therapeutic use; Interferons, therapeutic use; Monoclonal antibodies, therapeutic use

Indexed keywords

ALPHA2A INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO;

DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; INSTRUMENT VALIDATION; MONOTHERAPY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; TREATMENT OUTCOME;

HEALTH STATUS; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 51749088594     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822100-00004     Document Type: Review

References (50)

1. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994; 343: 271-5
2. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-52
3. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. Brain 1989; 112: 133-46
4. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11
5. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician 2004; 70: 1935-44
6. Division of Mental Health, World Health Organization. The World Health Organization quality of life-100. Geneva: World Health Organization, 1995
7. Schipper H, Clinch JJ, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: Spiler B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996: 11-23
8. Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part II. Quality of life. Can J Neurol Sci 1998; 25: 31-8
9. Bethoux F, Miller DM, Kinkel RP. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life. Mult Scler 2001; 7: 137-42
10. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
11. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76
13. PRISMS Study Group. Randomised, double-blind, placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-504
14. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl Med 2006; 354: 899-910
15. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 335-46
16. Nortvedt MW, Riise T, Myhr KM, et al. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999; 53: 1098-103
17. Hermann BP, Vickrey B, Hays RD, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996; 25: 113-8
18. Riazi A, Hobart JC, Lamping DL, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry 2003; 74: 710-4
19. Rothwell PM, McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997; 314: 1580-3
20. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
21. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
22. Ritvo PG, Fischer JF, Miller DM, et al. Multiple sclerosis quality of life inventory: a user's manual. New York (NY): National Multiple Sclerosis Society, 1997
23. National Multiple Sclerosis Society, Consortium of Multiple Sclerosis Centers. Multiple sclerosis quality of life inventory: a user's manual. New York: National Multiple Sclerosis Society, 1997
24. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206
25. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129-39
26. Ford HL, Gerry E, Tennant A, et al. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehab 2001; 15: 247-58
27. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2: 169-80
28. Marrie RM, Miller DM, Chelune GJ, et al. Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis. Mult Scler 2003; 9: 621-6
29. Lankhorst GJ, Jelles F, Smits RC, et al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). J Neurol 1996; 243: 469-74
30. Schwartz CE, Couldhard-Morris L, Zeng Q, et al. Measuring self-efficacy in people with multiple sclerosis: a validation study. Arch Phys Med Rehab 1996; 77: 394-8
31. Ferrans CE, Powers MJ. Quality of life index: development and psychometric properties. Res Nurs Health 1985; 15: 29-38
32. Simeoni M, Auquier P, Fernandez O, et al. Validation of the Multiple Sclerosis Quality of Life Questionnaire. Mult Scler 2008; 14: 219-30
33. Gold SM, Heesen C, Schulz H, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler 2001; 7: 119-30
34. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962-73
35. Rotstein Z, Barak Y, Noy S, et al. Quality of life in multiple sclerosis: development and validation of the 'RAYS' Scale and comparison with the SF-36. Int J Qual Health Care 2000; 12: 511-7
36. Freeman JA, Hobart JC, Thompson AJ. Does adding MS-specific items to a generic measure (the SF-36) improve measurement? Neurology 2001; 57: 68-74
37. Miller DM, Cohen JA, Kooijmans M, et al. Change in clinicain-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study. Mult Scler 2006; 12: 180-6
38. Pfennings LEMA, van der Oloeg HM, Cohen L, et al. A comparison of responsiveness indices in multiple sclerosis patients. Qual Life Res 1999; 8: 481-9
39. Gruenewald DA, Higginson IJ, Vivat B, et al. Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review. Mult Scler 2004; 10: 690-704
40. Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000; 68: 144-9
41. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23
42. Nortvedt MW, Riise T, Myhr KM, et al. Type 1 interferons and the quality of life of multiple sclerosis patients: results from a clinical trial on interferon alfa-2a. Mult Scler 1999; 5: 317-22
43. Vermersch P, de Seze J, Delisse B, et al. Quality of life in multiple sclerosis: influence of interferon-β1a (Avonex®) treatment. Mult Scler 2002; 8: 377-81
44. Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003; 216: 113-8
45. Arnoldus JHA, Killestein J, Pfennings LEMA, et al. Quality of life during the first 6 months of interferon-β treatment in patients with MS. Mult Scler 2000; 6: 338-42
46. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-β1b in the treatment of secondary progressive MS: impact of quality of life. Neurology 2001; 57: 1870-5
47. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87
48. Simone IL, Ceccarelli A, Tortorella C, et al. Influence of interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 2006; 4: 96
49. Lily O, McFadden E, Hensor E, et al. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 2006; 12: 808-13
50. Rice GP, Oger J, Duquette P, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci 1999; 26: 276-82